Barclays PLC Has $1.74 Million Stake in Replimune Group, Inc. (NASDAQ:REPL)

Barclays PLC raised its position in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 165.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 158,491 shares of the company's stock after acquiring an additional 98,791 shares during the period. Barclays PLC owned approximately 0.23% of Replimune Group worth $1,738,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Point72 DIFC Ltd acquired a new position in Replimune Group during the 2nd quarter valued at $57,000. Arizona State Retirement System acquired a new position in shares of Replimune Group during the second quarter valued at about $108,000. Quest Partners LLC raised its position in shares of Replimune Group by 30.4% during the second quarter. Quest Partners LLC now owns 13,510 shares of the company's stock valued at $122,000 after buying an additional 3,150 shares during the last quarter. Erste Asset Management GmbH bought a new stake in shares of Replimune Group in the third quarter valued at about $133,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Replimune Group by 82.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company's stock worth $144,000 after buying an additional 5,926 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts have commented on REPL shares. JPMorgan Chase & Co. upped their price target on Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a report on Tuesday, September 24th. Jefferies Financial Group upped their target price on Replimune Group from $16.00 to $19.00 and gave the company a "buy" rating in a research note on Wednesday, December 4th. BMO Capital Markets lifted their price target on shares of Replimune Group from $14.00 to $18.00 and gave the stock an "outperform" rating in a research note on Friday, November 22nd. Finally, HC Wainwright restated a "buy" rating and issued a $17.00 price objective on shares of Replimune Group in a research note on Friday, November 22nd. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $17.29.

Insiders Place Their Bets

In related news, CEO Sushil Patel sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $12.42, for a total value of $124,200.00. Following the completion of the sale, the chief executive officer now owns 202,014 shares of the company's stock, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Konstantinos Xynos sold 7,246 shares of the company's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $10.78, for a total value of $78,111.88. Following the transaction, the insider now directly owns 109,885 shares in the company, valued at approximately $1,184,560.30. This represents a 6.19 % decrease in their position. The disclosure for this sale can be found here. Insiders own 8.80% of the company's stock.

Replimune Group Price Performance

Replimune Group stock traded down $0.47 during mid-day trading on Friday, hitting $11.06. 772,275 shares of the company were exchanged, compared to its average volume of 735,396. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The company has a quick ratio of 10.11, a current ratio of 10.11 and a debt-to-equity ratio of 0.18. The business has a fifty day moving average of $12.39 and a 200 day moving average of $11.14. The company has a market capitalization of $756.69 million, a PE ratio of -3.63 and a beta of 1.28.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07. As a group, sell-side analysts expect that Replimune Group, Inc. will post -2.91 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.